News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
783,566 Results
Type
Article (67651)
Company Profile (125)
Press Release (715790)
Multimedia
Podcasts (114)
Webinars (13)
Section
Business (220354)
Career Advice (3014)
Deals (37033)
Drug Delivery (120)
Drug Development (88522)
Employer Resources (177)
FDA (17382)
Job Trends (15758)
News (373161)
Policy (35361)
Tag
Academia (2949)
Academic (2)
Accelerated approval (5)
Adcomms (27)
Allergies (94)
Alliances (55120)
ALS (99)
Alzheimer's disease (1493)
Antibody-drug conjugate (ADC) (156)
Approvals (17358)
Artificial intelligence (292)
Autoimmune disease (28)
Automation (16)
Bankruptcy (349)
Best Places to Work (12265)
BIOSECURE Act (21)
Biosimilars (117)
Biotechnology (99)
Bladder cancer (85)
Brain cancer (32)
Breast cancer (300)
Cancer (2414)
Cardiovascular disease (204)
Career advice (2539)
Career pathing (34)
CAR-T (172)
Cell therapy (474)
Cervical cancer (21)
Clinical research (71438)
Collaboration (908)
Company closure (1)
Compensation (550)
Complete response letters (30)
COVID-19 (2837)
CRISPR (46)
C-suite (265)
Cystic fibrosis (107)
Data (2256)
Decentralized trials (2)
Denatured (31)
Depression (53)
Diabetes (293)
Diagnostics (6822)
Digital health (18)
Diversity (6)
Diversity, equity & inclusion (43)
Drug discovery (132)
Drug pricing (120)
Drug shortages (32)
Duchenne muscular dystrophy (100)
Earnings (89798)
Editorial (45)
Employer branding (21)
Employer resources (154)
Events (126276)
Executive appointments (771)
FDA (18702)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (801)
Gene editing (117)
Generative AI (29)
Gene therapy (350)
GLP-1 (842)
Government (4854)
Grass and pollen (6)
Guidances (67)
Healthcare (20252)
Huntington's disease (25)
IgA nephropathy (31)
Immunology and inflammation (146)
Indications (30)
Infectious disease (2995)
Inflammatory bowel disease (151)
Inflation Reduction Act (10)
Influenza (55)
Intellectual property (101)
Interviews (606)
IPO (16987)
IRA (50)
Job creations (3908)
Job search strategy (2085)
Kidney cancer (11)
Labor market (37)
Layoffs (547)
Leadership (24)
Legal (8420)
Liver cancer (80)
Lung cancer (343)
Lymphoma (159)
Machine learning (7)
Management (62)
Manufacturing (339)
MASH (75)
Medical device (14213)
Medtech (14218)
Mergers & acquisitions (20639)
Metabolic disorders (783)
Multiple sclerosis (86)
NASH (23)
Neurodegenerative disease (113)
Neuropsychiatric disorders (34)
Neuroscience (2089)
NextGen: Class of 2025 (7071)
Non-profit (4841)
Now hiring (32)
Obesity (422)
Opinion (266)
Ovarian cancer (77)
Pain (98)
Pancreatic cancer (86)
Parkinson's disease (156)
Partnered (24)
Patents (246)
Patient recruitment (116)
Peanut (51)
People (63319)
Pharmaceutical (27)
Pharmacy benefit managers (20)
Phase I (22213)
Phase II (31192)
Phase III (23383)
Pipeline (1251)
Policy (167)
Postmarket research (3098)
Preclinical (9928)
Press Release (71)
Prostate cancer (113)
Psychedelics (38)
Radiopharmaceuticals (269)
Rare diseases (424)
Real estate (6463)
Recruiting (69)
Regulatory (24375)
Reports (43)
Research institute (2581)
Resumes & cover letters (463)
Rett syndrome (5)
RNA editing (5)
RSV (49)
Schizophrenia (79)
Series A (143)
Series B (90)
Service/supplier (9)
Sickle cell disease (56)
Special edition (17)
Spinal muscular atrophy (163)
Sponsored (30)
Startups (3827)
State (2)
Stomach cancer (16)
Supply chain (74)
Tariffs (46)
The Weekly (81)
Vaccines (802)
Venture capitalists (44)
Weight loss (301)
Women's health (36)
Worklife (20)
Date
Today (161)
Last 7 days (975)
Last 30 days (2797)
Last 365 days (34516)
2025 (11480)
2024 (37058)
2023 (42191)
2022 (53473)
2021 (58164)
2020 (56719)
2019 (49835)
2018 (37767)
2017 (35069)
2016 (35564)
2015 (41819)
2014 (36246)
2013 (32372)
2012 (34350)
2011 (34497)
2010 (33531)
Location
Africa (1036)
Alabama (57)
Alaska (7)
Arizona (230)
Arkansas (14)
Asia (45756)
Australia (8050)
California (6254)
Canada (2043)
China (560)
Colorado (277)
Connecticut (293)
Delaware (152)
Europe (104461)
Florida (937)
Georgia (214)
Idaho (59)
Illinois (580)
India (28)
Indiana (322)
Iowa (10)
Japan (169)
Kansas (109)
Kentucky (24)
Louisiana (11)
Maine (70)
Maryland (928)
Massachusetts (4785)
Michigan (243)
Minnesota (400)
Mississippi (2)
Missouri (90)
Montana (30)
Nebraska (26)
Nevada (64)
New Hampshire (70)
New Jersey (1787)
New Mexico (31)
New York (1793)
North Carolina (1075)
North Dakota (8)
Northern California (2747)
Ohio (215)
Oklahoma (15)
Oregon (35)
Pennsylvania (1403)
Puerto Rico (13)
Rhode Island (33)
South America (1397)
South Carolina (24)
South Dakota (1)
Southern California (2361)
Tennessee (103)
Texas (921)
United States (24018)
Utah (187)
Virginia (154)
Washington D.C. (63)
Washington State (573)
West Virginia (3)
Wisconsin (59)
783,566 Results for "xi an jiaotong university".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Anthos Therapeutics Shares New Data from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age or Bleeding Risk
March 31, 2025
·
9 min read
Press Releases
Restore Robotics Receives FDA 510(k) Clearance for Remanufacturing Da Vinci Xi 8mm Monopolar Curved Scissors
March 26, 2025
·
2 min read
Genetown
First-Ever Cost-Effectiveness Analysis of a Factor XI Inhibitor Demonstrates that Abelacimab, if Approved, Could Offer Significant Cost Savings as Compared to a Current Standard of Care Anticoagulant
Results of the first-ever cost-effectiveness study of a Factor XI inhibitor were presented during sessions of the Professional Society for Health Economics and Outcomes Research annual meeting.
May 6, 2024
·
11 min read
Press Releases
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
December 19, 2024
·
11 min read
Press Releases
Fresenius Kabi Receives FDA 510(k) Clearance for Adaptive Nomogram, Enhancing Plasma Collection Efficiency with the Aurora Xi Plasmapheresis System
January 28, 2025
·
6 min read
Press Releases
Sirius Therapeutics Announces Promising Phase I Clinical Data from Its Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders
December 9, 2024
·
3 min read
Press Releases
Data Published Today in the New England Journal of Medicine Demonstrates Anthos Therapeutics’ novel Factor XI inhibitor, Abelacimab 150mg, Reduced Major or Clinically Relevant Non-Major Bleeding by 62% Compared to Rivaroxaban (Xarelto) in Patients with Atrial Fibrillation
January 23, 2025
·
7 min read
Press Releases
Sirius Therapeutics to Present Data from Its Phase 1 Clinical Trial of Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders at the 66th ASH Annual Meeting and Exposition
December 3, 2024
·
2 min read
Drug Development
Sirius Therapeutics Begins Phase 1 Clinical Trial of Next-Generation, Long-Acting Factor XI siRNA Anticoagulant for Treatment of Thromboembolic Disorders
Sirius Therapeutics, announced it has dosed the first subject in a Phase 1, first-in-human clinical trial in Australia of SRSD107 on January 30th 2024, its next generation siRNA therapeutic targeting coagulation Factor XI, for the prevention and treatment of thromboembolic disorders.
February 1, 2024
·
2 min read
Press Releases
Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban
November 18, 2024
·
6 min read
1 of 78,357
Next
